U.S. Acknowledges Cannabis Medical Value: What's Next?

The federal government has officially acknowledged cannabis has accepted medical uses, marking a significant policy shift after decades of maintaining that marijuana has "no accepted medical use."

The acknowledgment came as part of the rescheduling process that would move cannabis from Schedule I to Schedule III of the Controlled Substances Act. The DEA is expected to finalize the change following a public comment period.

"This is a critical step forward," said Dr. Emily Carson, a cannabis researcher. "But the implications are complex and will require careful navigation."

What Changes

Schedule I substances are defined as having "no currently accepted medical use and a high potential for abuse." Moving to Schedule III acknowledges medical value while maintaining federal control over the substance.

The rescheduling would have several practical effects:

• Cannabis businesses could deduct normal business expenses on federal taxes (currently prohibited under Section 280E)
• Research restrictions would ease, allowing more clinical studies
• Banks and financial institutions would face reduced federal risk in serving cannabis companies
• Medical cannabis programs could operate with less federal interference

However, rescheduling does NOT federally legalize cannabis. It would remain a controlled substance subject to DEA regulation, and recreational use would still be federally illegal.

Industry Implications

The tax change alone could transform cannabis company finances. Section 280E currently prevents cannabis businesses from deducting rent, salaries, marketing, and other ordinary expenses—forcing effective tax rates often exceeding 70%.

Removing that burden would make many currently unprofitable operations viable and allow profitable companies to reinvest more in growth, product development, and employee compensation.

Banking access remains a question mark. While Schedule III status might reduce banks' concerns, comprehensive federal legislation protecting financial institutions serving cannabis companies would still be necessary for widespread banking participation.

Research Opportunities

Scientists have long argued that Schedule I restrictions make cannabis research unnecessarily difficult. Moving to Schedule III would ease—though not eliminate—barriers to studying cannabis for medical applications.

This could accelerate clinical trials, provide better data on dosing and efficacy for various conditions, and potentially lead to FDA-approved cannabis medications.

Timeline

The DEA is reviewing public comments submitted during the comment period. Once finalized, the rescheduling would take effect relatively quickly, though legal challenges are possible.

---

This article is based on original reporting by High Times.